

# Stuart J Knechtle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3173592/publications.pdf>

Version: 2024-02-01

311  
papers

16,669  
citations

14655

66  
h-index

19749

117  
g-index

463  
all docs

463  
docs citations

463  
times ranked

10973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the editor in response to: Measuring success in pig to non-human-primate renal xenotransplantation: Systematic review and comparative outcomes analysis of 1051 life sustaining NHP renal allo- and xeno-transplants by Firl and Markmann. American Journal of Transplantation, 2022, 22, 1933-1934.	4.7	1
2	Introducing thymus for promoting transplantation tolerance. Journal of Allergy and Clinical Immunology, 2022, 150, 549-556.	2.9	5
3	Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney International, 2021, 99, 161-172.	5.2	27
4	Definition and Analysis of Textbook Outcome: A Novel Quality Measure in Kidney Transplantation. World Journal of Surgery, 2021, 45, 1504-1513.	1.6	12
5	Point-of-Care Assessment of DCD Livers During Normothermic Machine Perfusion in a Nonhuman Primate Model. Hepatology Communications, 2021, 5, 1527-1542.	4.3	7
6	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology, 2021, 12, 694763.	4.8	16
7	Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. Frontiers in Immunology, 2021, 12, 660900.	4.8	7
8	Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells. Frontiers in Immunology, 2021, 12, 705140.	4.8	4
9	Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. Journal of Clinical Medicine, 2021, 10, 3656.	2.4	5
10	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	12.8	29
11	Optical coherence tomography of small intestine allograft biopsies using a handheld surgical probe. Journal of Biomedical Optics, 2021, 26, .	2.6	4
12	Another Step Toward Becoming a Transplant Community. Annals of Surgery, 2021, 273, e149-e150.	4.2	0
13	A Historical Cohort in Kidney Transplantation: 55-Year Follow-Up of 72 HLA-Identical, Donor-Recipient Pairs. Journal of Clinical Medicine, 2021, 10, 5505.	2.4	1
14	A cell-based multiplex immunoassay platform using fluorescent protein-barcoded reporter cell lines. Communications Biology, 2021, 4, 1338.	4.4	6
15	B cells in transplant tolerance and rejection: friends or foes?. Transplant International, 2020, 33, 30-40.	1.6	36
16	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
17	Percutaneous Splenorenal Shunt Creation in a Patient with Chronic Portomesenteric Thrombosis. Journal of Vascular and Interventional Radiology, 2020, 31, 1408-1409.	0.5	2
18	Outcomes in Kidney Transplantation Between Veterans Affairs and Civilian Hospitals. Annals of Surgery, 2020, 272, 506-510.	4.2	5

#	ARTICLE	IF	CITATIONS
19	Pharmacological approaches to antibody-mediated rejection“Are we getting closer?. American Journal of Transplantation, 2020, 20, 2637-2638.	4.7	2
20	Experimental modeling of desensitization: What have we learned about preventing AMR?. American Journal of Transplantation, 2020, 20, 2-11.	4.7	12
21	Textbook Outcomes in Liver Transplantation. World Journal of Surgery, 2020, 44, 3470-3477.	1.6	40
22	Targeting Calcium Release“activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. Transplantation, 2020, 104, 970-980.	1.0	0
23	Donor apoptotic cell“based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients. American Journal of Transplantation, 2020, 20, 2728-2739.	4.7	9
24	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
25	Antibody-Mediated Graft Rejection in Nonhuman Primate Models: Comparison of Sensitized Allograft and Xenograft Rejection. , 2020, , 157-164.		1
26	Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy. American Journal of Gastroenterology, 2020, 115, 1935-1935.	0.4	0
27	Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. American Journal of Transplantation, 2019, 19, 724-736.	4.7	61
28	Translational impact of NIH-funded nonhuman primate research in transplantation. Science Translational Medicine, 2019, 11, .	12.4	27
29	Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0220527.	2.5	46
30	The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. Journal of the American Geriatrics Society, 2019, 67, 794-798.	2.6	43
31	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. Journal of the American Society of Nephrology: JASN, 2019, 30, 1206-1219.	6.1	85
32	A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?. Transplantation, 2019, 103, 1675-1682.	1.0	10
33	Improvement in Liver Transplant Outcomes From Older Donors. Annals of Surgery, 2019, 270, 333-339.	4.2	36
34	Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation. Transplantation Reviews, 2019, 33, 115-129.	2.9	10
35	Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2019, 30, 2399-2411.	6.1	51
36	The past, present, and future of costimulation blockade in organ transplantation. Current Opinion in Organ Transplantation, 2019, 24, 391-401.	1.6	36

#	ARTICLE	IF	CITATIONS
37	Early Course of the Patient With a Kidney Transplant. , 2019, , 198-211.		1
38	Results of Renal Transplantation. , 2019, , 684-708.		2
39	Toward Long-term Livers. <i>Annals of Surgery</i> , 2019, 269, 28-29.	4.2	0
40	Parallels between antibody-mediated rejection and ischemic kidney injury with respect to B cell activation. <i>Annals of Translational Medicine</i> , 2019, 7, S151-S151.	1.7	1
41	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	4.7	205
42	Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. <i>Transplantation Reviews</i> , 2018, 32, 119-126.	2.9	12
43	The Volume-outcome Relationship in Deceased Donor Kidney Transplantation and Implications for Regionalization. <i>Annals of Surgery</i> , 2018, 267, 1169-1172.	4.2	18
44	Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes. <i>Transplantation Direct</i> , 2018, 4, e349.	1.6	20
45	Identification and Management of Abdominal Wall Varices in Pregnancy. <i>Obstetrics and Gynecology</i> , 2018, 132, 882-887.	2.4	6
46	IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade. <i>Frontiers in Immunology</i> , 2018, 9, 2323.	4.8	7
47	Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2018, 22, e13305.	1.0	27
48	Contemporary Strategies and Barriers to Transplantation Tolerance. <i>Transplantation</i> , 2018, 102, 1213-1222.	1.0	23
49	Improved survival in simultaneous lung-liver recipients and candidates in the modern era of lung allocation. <i>Journal of Surgical Research</i> , 2018, 231, 395-402.	1.6	9
50	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. <i>Clinical Transplantation</i> , 2018, 32, e13388.	1.6	6
51	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 410-420.	2.0	13
52	Thrombalexin: Use of a Cytotoxic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 2055-2064.	4.7	14
53	Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1991-1996.	6.1	67
54	Crosstalk Between T and B Cells in the Germinal Center After Transplantation. <i>Transplantation</i> , 2017, 101, 704-712.	1.0	51

#	ARTICLE	IF	CITATIONS
55	Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. <i>Transplantation Direct</i> , 2017, 3, e206.	1.6	9
56	Elevated HbA1c in donor organs from patients without a diagnosis of diabetes portends worse liver allograft survival. <i>Clinical Transplantation</i> , 2017, 31, e13047.	1.6	1
57	Hypoxia of the growing liver accelerates regeneration. <i>Surgery</i> , 2017, 161, 666-679.	1.9	73
58	Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. <i>Blood Advances</i> , 2017, 1, 2115-2119.	5.2	39
59	Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1615.	4.8	4
60	Portal hypertensive bleeding. , 2017, , 1218-1230.e3.		0
61	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	4.7	451
62	Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. <i>American Journal of Transplantation</i> , 2016, 16, 1726-1738.	4.7	37
63	One Size Does Not Fit All—Regional Variation in the Impact of the Share 35 Liver Allocation Policy. <i>American Journal of Transplantation</i> , 2016, 16, 137-142.	4.7	34
64	Reply to: "Percutaneous Management of Benign Biliary Strictures: Is It Time to Focus on Reducing Procedure Invasiveness?". <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 936-937.	0.5	0
65	Expanding the Donor Pool With Normothermic Ex Vivo Liver Perfusion: The Future Is Now. <i>American Journal of Transplantation</i> , 2016, 16, 3075-3076.	4.7	13
66	Regulating T Cell Behavior. <i>American Journal of Transplantation</i> , 2016, 16, 1949-1950.	4.7	2
67	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. <i>American Journal of Transplantation</i> , 2016, 16, 2612-2623.	4.7	18
68	Percutaneous Management of Benign Biliary Strictures with Large-Bore Catheters: Comparison between Patients with and without Orthotopic Liver Transplantation. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 219-225.e1.	0.5	25
69	Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 626-636.	6.1	58
70	Surgical Technique in Transplantation: How Much Does It Matter?. <i>American Journal of Transplantation</i> , 2015, 15, 2791-2792.	4.7	3
71	The Association Between Hospital Finances and Complications After Complex Abdominal Surgery. <i>Annals of Surgery</i> , 2015, 262, 273-279.	4.2	31
72	Longitudinal Studies of a B Cell-Derived Signature of Tolerance in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 2908-2920.	4.7	87

#	ARTICLE	IF	CITATIONS
73	Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. <i>Transplantation</i> , 2015, 99, 2485-2493.	1.0	13
74	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174.	4.1	51
75	Equalizing MELD Scores Over Broad Geographies Is Not the Most Efficacious Way to Allocate a Scarce Resource in a Value-based Environment. <i>Annals of Surgery</i> , 2015, 262, 220-223.	4.2	8
76	Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model. <i>American Journal of Transplantation</i> , 2015, 15, 815-822.	4.7	56
77	Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. <i>Hepatology</i> , 2015, 61, 843-856.	7.3	6
78	Belatacept: Is There BENEFIT for Liver Transplantation Too?. <i>American Journal of Transplantation</i> , 2014, 14, 1717-1718.	4.7	11
79	Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. <i>Liver Transplantation</i> , 2014, 20, 100-115.	2.4	51
80	Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2014, 14, 59-69.	4.7	157
81	Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. <i>Journal of Surgical Oncology</i> , 2014, 109, 533-541.	1.7	22
82	The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. <i>American Journal of Transplantation</i> , 2014, 14, 779-787.	4.7	182
83	Urine proteomics in kidney transplantation. <i>Transplantation Reviews</i> , 2014, 28, 15-20.	2.9	35
84	An Introduction to Pediatric Organ Transplantation. , 2014, , 1353-1356.		0
85	Transplant Clinic Management. , 2014, , 1518-1532.		0
86	Abdominal Solid Organ Transplantation Fellowship Training. , 2014, , 1562-1565.		0
87	Medical Solid Organ Transplant Fellowship Training. , 2014, , 1566-1571.		0
88	Laparoscopic vs Open Right Hepatectomy: A Value-Based Analysis. <i>Journal of the American College of Surgeons</i> , 2014, 218, 929-939.	0.5	58
89	Administration of Organ Procurement and Allocation. , 2014, , 251-263.		0
90	Results of Renal Transplantation. , 2014, , 676-697.		1

#	ARTICLE	IF	CITATIONS
91	Preface to the Seventh Edition. , 2014, , xi.		0
92	Early Course of the Patient with Kidney Transplant. , 2014, , 204-215.		0
93	Domino Liver Transplantation in Maple Syrup Urine Disease: A Case Report and Review of the Literature. Transplantation Proceedings, 2013, 45, 806-809.	0.6	27
94	Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques ( <i>Macaca mulatta</i> ). Experimental and Toxicologic Pathology, 2013, 65, 1019-1024.	2.1	8
95	Reply to Vanhove. Transplant International, 2013, 26, e26-e27.	1.6	0
96	Induction immunosuppression in liver transplantation: a review. Transplant International, 2013, 26, 673-683.	1.6	63
97	Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts. New England Journal of Medicine, 2013, 369, 20-31.	27.0	312
98	Lymphodepletional Strategies in Transplantation. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015511-a015511.	6.2	24
99	Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology, 2013, 57, 708-715.	7.3	88
100	Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transplant International, 2013, 26, 592-600.	1.6	24
101	Starting Well: Induction Immunosuppression after Organ Transplantation. Transplant International, 2013, 26, 661-661.	1.6	0
102	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013, 174, 364-371.	2.6	41
103	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. PLoS ONE, 2013, 8, e74225.	2.5	49
104	Humoral Immunity Induced By Viral Infection Provides a Major Barrier To Hematopoietic Cell Transplantation. Blood, 2013, 122, 894-894.	1.4	1
105	Tolerogenic therapies in transplantation. Frontiers in Immunology, 2012, 3, 198.	4.8	58
106	Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology, 2012, 56, 2071-2081.	7.3	34
107	The role of B cells in solid organ transplantation. Seminars in Immunology, 2012, 24, 96-108.	5.6	35
108	The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis. American Journal of Pathology, 2012, 181, 1693-1701.	3.8	48

#	ARTICLE	IF	CITATIONS
109	Enhanced De Novo Alloantibody and Antibody-Mediated Injury in Rhesus Macaques. American Journal of Transplantation, 2012, 12, 2395-2405.	4.7	24
110	Patterns of De Novo Allo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment. American Journal of Transplantation, 2012, 12, 2641-2651.	4.7	29
111	Biologics in organ transplantation. Transplant International, 2012, 25, 707-719.	1.6	26
112	Location of portosystemic shunting. , 2012, , 1146-1158.e3.		0
113	Seek and You Will Find: Antibody and the Liver. American Journal of Transplantation, 2011, 11, 424-425.	4.7	4
114	Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney Transplants. American Journal of Transplantation, 2011, 11, 841-847.	4.7	92
115	Guidance for Liver Transplant Immunosuppression. American Journal of Transplantation, 2011, 11, 886-887.	4.7	3
116	Miles to Go. American Journal of Transplantation, 2011, 11, 1119-1120.	4.7	16
117	Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-enhanced MR Imaging. Comparison to Prior Same-Center Results after MR Systems Improvements. Radiology, 2011, 261, 824-833.	7.3	51
118	Primary Vascularization of the Graft Determines the Immunodominance of Murine Minor H Antigens during Organ Transplantation. Journal of Immunology, 2011, 187, 3997-4006.	0.8	17
119	Interleukin-15 Receptor Blockade in Non-Human Primate Kidney Transplantation. Transplantation, 2010, 89, 937-944.	1.0	11
120	Cytokine kinetics profiling in pediatric renal transplant recipients. Pediatric Transplantation, 2010, 14, 636-645.	1.0	0
121	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.8	18
122	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1197-1204.	0.5	16
123	Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagnostic Microbiology and Infectious Disease, 2010, 66, 7-15.	1.8	42
124	Immunoregulation and Tolerance. Transplantation Proceedings, 2010, 42, S13-S15.	0.6	12
125	Prevention trumps treatment of antibody-mediated transplant rejection. Journal of Clinical Investigation, 2010, 120, 1036-1039.	8.2	5
126	Unique Aspects of Rejection and Tolerance in Liver Transplantation. Seminars in Liver Disease, 2009, 29, 091-101.	3.6	73



#	ARTICLE	IF	CITATIONS
127	Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2009, 36, 2224-2230.	2.0	59
128	Early and Limited Use of Tacrolimus to Avoid Rejection in an Alemtuzumab and Sirolimus Regimen for Kidney Transplantation: Clinical Results and Immune Monitoring. <i>American Journal of Transplantation</i> , 2009, 9, 1087-1098.	4.7	67
129	BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab. <i>American Journal of Transplantation</i> , 2009, 9, 1835-1845.	4.7	88
130	HLA-C and Liver Transplant Outcomes: Interpreting the Facts. <i>American Journal of Transplantation</i> , 2009, 9, 1491-1492.	4.7	3
131	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation</i> , 2009, 87, 125-132.	1.0	46
132	Overcoming Chronic Rejection—Can it B?. <i>Transplantation</i> , 2009, 88, 955-961.	1.0	37
133	Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine. <i>Transplantation</i> , 2009, 87, 1814-1820.	1.0	77
134	Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. <i>Liver Transplantation</i> , 2008, 14, 1461-1465.	2.4	38
135	Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. <i>Transplant International</i> , 2008, 21, 625-636.	1.6	34
136	Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2008, 12, 447-455.	1.0	34
137	CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H. <i>American Journal of Transplantation</i> , 2008, 8, 793-802.	4.7	158
138	Unaltered Graft Survival and Intragraft Lymphocytes Infiltration in the Cardiac Allograft of Cxcr3 <sup>hi</sup> /i <sup>hi</sup> Mouse Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 1593-1603.	4.7	34
139	Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells. <i>American Journal of Transplantation</i> , 2008, 8, 1529-1536.	4.7	69
140	A Comparison of Alemtuzumab with Basiliximab Induction in Simultaneous Pancreas–Kidney Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 1702-1710.	4.7	43
141	Surgical invention and commercialization. <i>Surgery</i> , 2008, 143, 175-181.	1.9	2
142	The Impact of Donor Variables on the Outcome of Orthotopic Liver Transplantation for Hepatitis C. <i>Transplantation Proceedings</i> , 2008, 40, 219-223.	0.6	31
143	Macrophages Driven to a Novel State of Activation Have Anti-Inflammatory Properties in Mice. <i>Journal of Immunology</i> , 2008, 180, 335-349.	0.8	80
144	Nonhuman Primate Infections after Organ Transplantation. <i>ILAR Journal</i> , 2008, 49, 209-219.	1.8	33

#	ARTICLE	IF	CITATIONS
145	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 812-824.	6.1	28
146	Early Course of the Patient with a Kidney Transplant. , 2008, , 210-219.		2
147	Results of Renal Transplantation. , 2008, , 657-675.		2
148	Vascular Access for Dialysis, Chemotherapy, and Nutritional Support. , 2008, , 1457-1468.		0
149	Developmental Exposure to Noninherited Maternal Antigens Induces CD4+T Regulatory Cells: Relevance to Mechanism of Heart Allograft Tolerance. <i>Journal of Immunology</i> , 2007, 179, 6749-6761.	0.8	59
150	Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3 <sup>+/+</sup> Mouse Recipients. <i>Journal of Immunology</i> , 2007, 179, 8016-8025.	0.8	18
151	Human CD4+CD25 <sup>low</sup> Adaptive T Regulatory Cells Suppress Delayed-Type Hypersensitivity during Transplant Tolerance. <i>Journal of Immunology</i> , 2007, 178, 3983-3995.	0.8	58
152	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 1429-1434.	1.0	35
153	Liver transplantation 2007: where do we go from here?. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 211-214.	1.6	0
154	Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. <i>Pediatric Transplantation</i> , 2007, 11, 661-670.	1.0	59
155	CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. <i>Immunology</i> , 2007, 120, 467-485.	4.4	45
156	Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab. <i>American Journal of Transplantation</i> , 2007, 7, 2619-2625.	4.7	194
157	Review: chemokines in transplantation. <i>Transplantation Reviews</i> , 2007, 21, 107-118.	2.9	3
158	Immunosuppression in nonhuman primates. <i>Transplantation Reviews</i> , 2006, 20, 131-138.	2.9	1
159	Determination of the Functional Status of Alloreactive T Cells by Interferon- $\gamma$ Kinetics. <i>Transplantation</i> , 2006, 81, 590-598.	1.0	16
160	T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients. <i>Transplantation</i> , 2006, 81, 81-87.	1.0	83
161	The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. <i>Transplant International</i> , 2006, 19, 705-714.	1.6	131
162	Outcomes at 3 $\frac{1}{2}$ years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. <i>Transplant International</i> , 2006, 19, 885-892.	1.6	66

#	ARTICLE	IF	CITATIONS
163	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. <i>American Journal of Transplantation</i> , 2006, 6, 876-883.	4.7	135
164	Elevation of multiple cytokines/chemokines in urine of human renal transplant recipients with acute and chronic injuries: potential usage for diagnosis and monitoring. <i>Transplantation Reviews</i> , 2006, 20, 165-171.	2.9	5
165	Donation After Cardiac Death. <i>Annals of Surgery</i> , 2005, 242, 724-731.	4.2	342
166	Simultaneous Pancreas-Kidney Transplantation From Donation After Cardiac Death. <i>Annals of Surgery</i> , 2005, 242, 716-723.	4.2	89
167	Selenium-Binding Protein-1 in Smooth Muscle Cells is Downregulated in a Rhesus Monkey Model of Chronic Allograft Nephropathy. <i>American Journal of Transplantation</i> , 2005, 5, 58-67.	4.7	14
168	Campath-1H Use in Pediatric Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1569-1573.	4.7	85
169	Liver transplantation for HELLP syndrome. <i>Liver Transplantation</i> , 2005, 11, 224-228.	2.4	85
170	Development of tolerogenic strategies in the clinic. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1739-1746.	4.0	14
171	How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 74-75.	2.0	1
172	Incidental living donor nephrectomy: a unique expansion of the donor pool. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 245-246.	0.7	0
173	Infected Bilomas in Liver Transplant Recipients: Clinical Features, Optimal Management, and Risk Factors for Mortality. <i>Clinical Infectious Diseases</i> , 2004, 39, 517-525.	5.8	46
174	Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF- $\beta$ 1+CD4+T Regulatory Cell Infiltrates. <i>Journal of Immunology</i> , 2004, 172, 5753-5764.	0.8	76
175	Elevation of CXCR3-Binding Chemokines in Urine Indicates Acute Renal-Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2004, 4, 432-437.	4.7	156
176	Infected Bilomas in Liver Transplant Recipients, Incidence, Risk Factors and Implications for Prevention. <i>American Journal of Transplantation</i> , 2004, 4, 574-582.	4.7	71
177	Donation After Cardiac Death: The University of Wisconsin Experience with Renal Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 1490-1494.	4.7	152
178	Campath-1H in renal transplantation: The University of Wisconsin experience. <i>Surgery</i> , 2004, 136, 754-760.	1.9	139
179	Superior Long-Term Results of Simultaneous Pancreas-Kidney Transplantation from Pediatric Donors. <i>American Journal of Transplantation</i> , 2004, 4, 2093-2101.	4.7	49
180	Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. <i>Pediatric Transplantation</i> , 2004, 8, 106-112.	1.0	41

#	ARTICLE	IF	CITATIONS
181	Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. <i>Transplant Immunology</i> , 2004, 13, 147-154.	1.2	3
182	Surveillance of Acute Rejection in Baboon Renal Transplantation by Elevation of Interferon- $\gamma$ Inducible Protein-10 and Monokine Induced by Interferon- $\gamma$ in Urine. <i>Transplantation</i> , 2004, 78, 1002-1007.	1.0	33
183	Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model1. <i>Transplantation</i> , 2004, 77, 914-920.	1.0	74
184	Metastable tolerance in nonhuman primates and humans. <i>Transplantation</i> , 2004, 77, 936-939.	1.0	30
185	Challenging Choices. <i>Annals of Surgery</i> , 2004, 239, 160-161.	4.2	2
186	Correlation Between Human Leukocyte Antigen Antibody Production and Serum Creatinine in Patients Receiving Sirolimus Monotherapy after Campath-1H Induction. <i>Transplantation</i> , 2004, 78, 919-924.	1.0	47
187	Hepatic steatosis and liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 123-129.	1.6	3
188	Clinical trials: where are we now?. <i>Immunological Reviews</i> , 2003, 196, 237-246.	6.0	5
189	Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. <i>American Journal of Transplantation</i> , 2003, 3, 722-730.	4.7	360
190	Alemtuzumab and tolerance: the university of wisconsin experience. <i>Transplantation Reviews</i> , 2003, 17, S26-S28.	2.9	0
191	Involvement of linker for activation of T cells in the costimulatory signaling pathways. <i>Transplantation Proceedings</i> , 2003, 35, 553-554.	0.6	0
192	An overview of the actions of cyclosporine and FK506. <i>Transplantation Reviews</i> , 2003, 17, 165-171.	2.9	11
193	Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. <i>International Immunology</i> , 2003, 15, 1369-1378.	4.0	10
194	Underutilization of pancreas donors. <i>Transplantation</i> , 2003, 75, 1271-1276.	1.0	103
195	Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection1. <i>Transplantation</i> , 2003, 76, 524-530.	1.0	37
196	Mycophenolate mofetil: what is the evidence that it decreases chronic rejection?. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 313-316.	1.6	0
197	Novel agents or strategies for immunosuppression after renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 172-178.	1.6	2
198	Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling1. <i>Transplantation</i> , 2003, 75, 1075-1077.	1.0	13

#	ARTICLE	IF	CITATIONS
199	Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts <sup>1</sup> . <i>Transplantation</i> , 2003, 75, 1677-1682.	1.0	51
200	From Eck's Fistula to TIPS. <i>Annals of Surgery</i> , 2003, 238, S49-S55.	4.2	6
201	Kidney Transplantation and Dialysis Access. , 2003, , 607-615.		0
202	Long-term outcomes in simultaneous pancreas-kidney transplantation: lessons relearned. <i>Clinical Transplants</i> , 2003, , 215-20.	0.2	1
203	Prolongation of Long-Term Kidney Graft Survival by a Simultaneous Liver Transplant: The Liver Does It, and the Heart Does It Too.. <i>Transplantation</i> , 2002, 74, 1370-1371.	1.0	3
204	Piceatannol in combination with low doses of cyclosporine a prolongs kidney allograft survival in a stringent rat transplantation model <sup>1,2</sup> . <i>Transplantation</i> , 2002, 74, 1609-1617.	1.0	12
205	Steps toward transplantation tolerance in the clinic. <i>Transplantation Proceedings</i> , 2001, 33, 3844-3845.	0.6	1
206	Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2001, 5, 594-602.	1.7	27
207	Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. <i>Immunological Reviews</i> , 2001, 183, 205-213.	6.0	41
208	What's new in transplantation. <i>Journal of the American College of Surgeons</i> , 2001, 192, 366-371.	0.5	1
209	Treatment with immunotoxin. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 681-689.	4.0	32
210	STUDIES OF PEDIATRIC LIVER TRANSPLANTATION (SPLIT): YEAR 2000 OUTCOMES. <i>Transplantation</i> , 2001, 72, 463-476.	1.0	119
211	IMMUNOTOXIN FN18-CRM9 INDUCES STRONGER T CELL SIGNALING THAN UNCONJUGATED MONOCLONAL ANTIBODY FN1812. <i>Transplantation</i> , 2001, 72, 496-503.	1.0	6
212	GRAFT SURVIVAL IN A RHESUS RENAL TRANSPLANT MODEL AFTER IMMUNOTOXIN-MEDIATED T-CELL DEPLETION IS ENHANCED BY MYCOPHENOLATE AND STEROIDS <sup>1,2</sup> . <i>Transplantation</i> , 2001, 72, 581-587.	1.0	9
213	SUCCESSFUL CONVERSION FROM CONVENTIONAL IMMUNOSUPPRESSION TO ANTI-CD154 MONOCLONAL ANTIBODY COSTIMULATORY MOLECULE BLOCKADE IN RHESUS RENAL ALLOGRAFT RECIPIENTS <sup>1,2</sup> . <i>Transplantation</i> , 2001, 72, 587-597.	1.0	38
214	Kidney Transplantation and Dialysis Access. , 2001, , 1449-1462.		0
215	Costimulatory Blockade as a Therapeutic Regimen for Prolonging Allograft Survival and Inducing Tolerance: An Overview of Recent Research. , 2001, , 127-158.		0
216	Tolerance induction. , 2001, , 149-168.		0

#	ARTICLE	IF	CITATIONS
217	Simultaneous Pancreas-Kidney (SPK) Transplantation from Controlled Non-Heart-Beating Donors (NHBDs). <i>Cell Transplantation</i> , 2000, 9, 889-893.	2.5	49
218	DETECTION OF CELLS RECOGNIZING DONOR GRAFT-DERIVED FIBROBLASTS IN THE BLOOD OF ALLOGRAFT-REJECTING ANIMALS.. <i>Transplantation</i> , 2000, 69, S152.	1.0	1
219	EARLY RESULTS IN THE USE OF THYMOGLOBULIN AND SIMULECT AS INDUCTION THERAPY IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS.. <i>Transplantation</i> , 2000, 69, S160.	1.0	0
220	CD40:CD154 interactions and allograft rejection. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 10-15.	1.6	10
221	IMMUNOREGULATION IN MONKEY KIDNEY ALLOGRAFT ACCEPTANCE: BYSTANDER SUPPRESSION OF DTH TRIGGERED BY DONOR ANTIGENS.. <i>Transplantation</i> , 2000, 69, S242.	1.0	1
222	LONG-TERM RESULTS OF LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER. <i>Transplantation</i> , 2000, 70, 780-783.	1.0	117
223	T-cell depletion as a means of achieving tolerance. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 96-102.	1.6	7
224	Simultaneous Pancreas-Kidney Transplantation and Living Related Donor Renal Transplantation in Patients With Diabetes: Is There a Difference in Survival?. <i>Annals of Surgery</i> , 2000, 231, 417-423.	4.2	122
225	Knowledge about transplantation tolerance gained in primates. <i>Current Opinion in Immunology</i> , 2000, 12, 552-556.	5.5	36
226	Potential of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. <i>Blood</i> , 2000, 95, 2733-2741.	1.4	13
227	Regulation of T Cell Receptor- and CD28-induced Tyrosine Phosphorylation of the Focal Adhesion Tyrosine Kinases Pyk2 and Fak by Protein Kinase C. <i>Journal of Biological Chemistry</i> , 2000, 275, 1344-1350.	3.4	14
228	Liver transplantation from controlled non-heart-beating donors. <i>Surgery</i> , 2000, 128, 579-588.	1.9	177
229	INCREASED GLOMERULAR DEPOSITS OF VON WILLEBRAND FACTOR IN CHRONIC, BUT NOT ACUTE, REJECTION OF PRIMATE RENAL ALLOGRAFTS. <i>Transplantation</i> , 2000, 70, 877-886.	1.0	10
230	CD28 Ligation Induces Tyrosine Phosphorylation of Pyk2 but Not Fak in Jurkat T Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 6735-6740.	3.4	31
231	Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. <i>Clinical Transplantation</i> , 1999, 13, 349-355.	1.6	69
232	Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. <i>Nature Medicine</i> , 1999, 5, 686-693.	30.7	801
233	Ureteroneocystostomy for renal transplantation. <i>Journal of the American College of Surgeons</i> , 1999, 188, 707-709.	0.5	19
234	CD28 ligation induces rapid tyrosine phosphorylation of the linker molecule LAT in the absence of Syk and ZAP-70 tyrosine phosphorylation. <i>European Journal of Immunology</i> , 1999, 29, 2354-2359.	2.9	25

#	ARTICLE	IF	CITATIONS
235	Surgical portosystemic shunts for treatment of portal hypertensive bleeding: Outcome and effect on liver function. <i>Surgery</i> , 1999, 126, 708-713.	1.9	28
236	Utilization of pediatric donors for pancreas transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 610-611.	0.6	28
237	Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. <i>Transplantation Proceedings</i> , 1999, 31, 785.	0.6	3
238	ILIAC ARTERY PSEUDOANEURYSM FOLLOWING RENAL TRANSPLANTATION PRESENTING AS LUMBOSACRAL PLEXOPATHY. <i>Transplantation</i> , 1999, 67, 1077-1078.	1.0	45
239	THE IMPACT OF HYPOALBUMINEMIA IN KIDNEY-PANCREAS TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1999, 68, 72-75.	1.0	35
240	ACTIVATION OF T LYMPHOCYTES FOR ADHESION AND CYTOKINE EXPRESSION BY TOXIN-CONJUGATED ANTI-CD3 MONOCLONAL ANTIBODIES1. <i>Transplantation</i> , 1999, 68, 693-698.	1.0	11
241	ANALYSIS OF REJECTION AND ATN AFTER INDUCTION WITH ATG, BASILIXIMAB AND DACLIZIMAB IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, S546.	1.0	3
242	Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 1998, 4, 483-490.	1.8	39
243	Strategies for tolerance induction in nonhuman primates. <i>Current Opinion in Immunology</i> , 1998, 10, 513-517.	5.5	35
244	Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. <i>Human Immunology</i> , 1998, 59, 415-425.	2.4	20
245	Two distinct forms of soluble MHC class I molecules synthesized by different mechanisms in normal rat cells in vitro. <i>Human Immunology</i> , 1998, 59, 404-414.	2.4	11
246	Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. <i>Transplant Immunology</i> , 1998, 6, 169-175.	1.2	6
247	Infant pediatric liver transplantation results equal those for older pediatric patients. <i>Journal of Pediatric Surgery</i> , 1998, 33, 20-23.	1.6	57
248	Primate renal transplants using immunotoxin. <i>Surgery</i> , 1998, 124, 438-447.	1.9	65
249	Immunologic Risks of Combined Kidney&#x2013;Pancreas Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 249-250.	0.6	6
250	Donor Factors Affecting Outcome After Pancreas Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 276-277.	0.6	61
251	Enteric Conversion of Bladder-Drained Pancreas Allografts: Experience in 95 Patients. <i>Transplantation Proceedings</i> , 1998, 30, 441-442.	0.6	23
252	Reversal of acute allograft rejection using immunotoxin. <i>Transplantation Proceedings</i> , 1998, 30, 2150-2151.	0.6	7



#	ARTICLE	IF	CITATIONS
253	Living unrelated renal donation: The University of Wisconsin experience. <i>Surgery</i> , 1998, 124, 604-611.	1.9	79
254	PROCUREMENT, PRESERVATION, AND TRANSPORT OF CADAVER KIDNEYS. <i>Surgical Clinics of North America</i> , 1998, 78, 41-54.	1.5	33
255	Experience With 500 Simultaneous Pancreas-Kidney Transplants. <i>Annals of Surgery</i> , 1998, 228, 284-296.	4.2	275
256	ANALYSIS OF PRIMATE RENAL ALLOGRAFTS AFTER T-CELL DEPLETION WITH ANTI-CD3-CRM91,2. <i>Transplantation</i> , 1998, 66, 5-13.	1.0	49
257	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2. <i>Transplantation</i> , 1998, 66, 29-37.	1.0	273
258	POSTTRANSPLANT INFECTION IN ENTERIC VERSUS BLADDER-DRAINED SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1998, 66, 1746-1750.	1.0	96
259	A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION1. <i>Transplantation</i> , 1998, 66, 1751-1759.	1.0	72
260	Immunotoxins in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 1997, 2, 97.	1.6	0
261	CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 8789-8794.	7.1	905
262	Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers. <i>Human Gene Therapy</i> , 1997, 8, 1763-1772.	2.7	186
263	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. <i>Transplant International</i> , 1997, 10, 152-156.	1.6	8
264	Emergency Portacaval Shunts: Is Orloff Correct?. <i>HPB Surgery</i> , 1997, 10, 253-265.	2.2	0
265	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. <i>Transplant International</i> , 1997, 10, 152-156.	1.6	20
266	Identification of new Mamu-DRB alleles using DGGE and direct sequencing. <i>Immunogenetics</i> , 1997, 45, 171-179.	2.4	69
267	Proceed with Caution: Liver Transplantation for Metastatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 1997, 225, 345-346.	4.2	19
268	FN18-CRM9 IMMUNOTOXIN PROMOTES TOLERANCE IN PRIMATE RENAL ALLOGRAFTS1. <i>Transplantation</i> , 1997, 63, 1-6.	1.0	196
269	SPLIT TOLERANCE INDUCED BY IMMUNOTOXIN IN A RHESUS KIDNEY ALLOGRAFT MODEL1. <i>Transplantation</i> , 1997, 63, 1339-1345.	1.0	50
270	Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. <i>Surgery</i> , 1996, 120, 719-724.	1.9	6



#	ARTICLE	IF	CITATIONS
271	Gene therapy in transplantation. <i>Transplant Immunology</i> , 1996, 4, 257-264.	1.2	19
272	Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 1055-1059.	0.8	11
273	Risk factors for renal allograft loss in patients with systemic lupus erythematosus. <i>Kidney International</i> , 1996, 49, 512-517.	5.2	56
274	THE INFLUENCE OF NATIVE NEPHRECTOMY ON THE INCIDENCE OF RECURRENT DISEASE FOLLOWING RENAL TRANSPLANTATION FOR PRIMARY GLOMERULONEPHRITIS1. <i>Transplantation</i> , 1996, 61, 228-234.	1.0	66
275	IMMUNOSUPPRESSIVE EFFECTS OF AN HLA CLASS I-DERIVED PEPTIDE IN A RAT CARDIAC ALLOGRAFT MODEL. <i>Transplantation</i> , 1996, 61, 1222-1228.	1.0	26
276	DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1. <i>Transplantation</i> , 1996, 61, 1581-1586.	1.0	153
277	ADENOVIRUS-MEDIATED GENE TRANSFER INTO RAT CARDIAC ALLOGRAFTS. <i>Transplantation</i> , 1996, 61, 1726-1729.	1.0	40
278	CLINICAL HEPATITIS AFTER TRANSPLANTATION OF HEPATITIS C VIRUS-POSITIVE KIDNEYS. <i>Transplantation</i> , 1996, 62, 1758-1762.	1.0	23
279	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. <i>Transplantation</i> , 1995, 59, 631-647.	1.0	91
280	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. <i>Transplantation</i> , 1995, 59, 631-633.	1.0	56
281	PRETRANSPLANT STATUS AND PATIENT SURVIVAL FOLLOWING LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 60, 920-925.	1.0	10
282	Living Related and Unrelated Donors for Kidney Transplantation A 28-Year Experience. <i>Annals of Surgery</i> , 1995, 222, 353-364.	4.2	91
283	SUCCESSFUL EXTRARENAL TRANSPLANTATION FROM NON-HEART-BEATING DONORS. <i>Transplantation</i> , 1995, 59, 977-982.	1.0	190
284	Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. <i>Surgery</i> , 1995, 118, 615-620.	1.9	92
285	Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. <i>Human Immunology</i> , 1994, 40, 191-201.	2.4	50
286	Use of Donor Serum to Prevent Passive Transfer of Hyperacute Rejection. <i>Journal of Surgical Research</i> , 1994, 57, 150-155.	1.6	7
287	100 Consecutive liver transplants in infants and children: An 8-year experience. <i>Journal of Pediatric Surgery</i> , 1994, 29, 1135-1140.	1.6	35
288	INDUCTION OF SPECIFIC TOLERANCE BY INTRATHYMIC INJECTION OF RECIPIENT MUSCLE CELLS TRANSFECTED WITH DONOR CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX. <i>Transplantation</i> , 1994, 57, 990-996.	1.0	56

#	ARTICLE	IF	CITATIONS
289	Human interleukin-2 and lymphoproliferative (T-helper cell) responses to soluble HLA class I antigens <i>in vitro</i> : I. Specificity for polymorphic domains <sup>1,2</sup> . Tissue Antigens, 1993, 42, 35-38.	1.0	6
290	A Controlled, Double-Blind, Randomized Trial of Verapamil and Cyclosporine in Cadaver Renal Transplant Patients. American Journal of Kidney Diseases, 1993, 21, 189-195.	1.9	24
291	Urological Complications in 210 Consecutive Simultaneous Pancreas-Kidney Transplants with Bladder Drainage. Annals of Surgery, 1993, 218, 561-570.	4.2	116
292	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATION—A MULTIVARIATE ANALYSIS. Transplantation, 1993, 55, 807-813.	1.0	937
293	RETRANSPLANTATION OF THE LIVER—A SEVEN-YEAR EXPERIENCE. Transplantation, 1993, 55, 1083-1086.	1.0	110
294	The Use of UW Solution in Clinical Transplantation A 4-year Experience. Annals of Surgery, 1992, 215, 579-585.	4.2	104
295	THE EFFECT OF DONOR AGE, RECIPIENT AGE, AND HLA MATCH ON IMMUNOLOGIC GRAFT SURVIVAL IN CADAVER RENAL TRANSPLANT RECIPIENTS <sup>1</sup> . Transplantation, 1992, 53, 55-58.	1.0	71
296	THE INFLUENCE OF RS-61443 ON ANTIBODY-MEDIATED REJECTION. Transplantation, 1992, 53, 696.	1.0	22
297	Experience With 100 Consecutive Simultaneous Kidney-Pancreas Transplants With Bladder Drainage. Annals of Surgery, 1991, 214, 703-711.	4.2	96
298	THE PREDICTIVE VALUE OF DONOR LIVER BIOPSIES FOR THE DEVELOPMENT OF PRIMARY NONFUNCTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1991, 51, 157-163.	1.0	346
299	MULTIVARIATE ANALYSIS OF DONOR-SPECIFIC VERSUS RANDOM TRANSFUSION PROTOCOLS IN HAPLOIDENTICAL LIVING-RELATED TRANSPLANTS. Transplantation, 1991, 51, 382-384.	1.0	13
300	ORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER. Transplantation, 1991, 51, 431-432.	1.0	65
301	The Effect of TLI and Cyclosporine on Xenograft Survival. Transplantation, 1990, 50, 1082.	1.0	6
302	Pneumatosis Intestinalis. Annals of Surgery, 1990, 212, 160-165.	4.2	205
303	Irradiation for xenogeneic transplantation. Radiotherapy and Oncology, 1990, 18, 29-37.	0.6	5
304	Anomalous biliary ducts associated with duodenal atresia. Journal of Pediatric Surgery, 1990, 25, 1266-1269.	1.6	40
305	HEPATIC TRANSPLANTATION INTO SENSITIZED RECIPIENTS. Transplantation, 1987, 43, 8-12.	1.0	79
306	XENOGRAFT SURVIVAL IN TWO SPECIES COMBINATIONS USING TOTAL-LYMPHOID IRRADIATION AND CYCLOSPORINE. Transplantation, 1987, 43, 173-175.	1.0	55

#	ARTICLE	IF	CITATIONS
307	INFILTRATING CELL PHENOTYPES AND PATTERNS ASSOCIATED WITH HEPATIC ALLOGRAFT REJECTION OR ACCEPTANCE. <i>Transplantation</i> , 1987, 43, 169-172.	1.0	26
308	The influence of dose and dose rate of total lymphoid irradiation in the rat cardiac allograft model. <i>Radiotherapy and Oncology</i> , 1987, 9, 311-318.	0.6	15
309	Î±1-Adrenergic effects and liver regeneration. <i>Hepatology</i> , 1987, 7, 1189-1194.	7.3	184
310	Identification of bacterial antigens in circulating immune complexes of infective endocarditis.. <i>Journal of Clinical Investigation</i> , 1982, 70, 271-280.	8.2	37
311	Harnessing the B Cell Response in Kidney Transplantation â€œ Current State and Future Directions. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5